These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2563231)

  • 41. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Paik JW; Lee MS; Cho BH; Park YM; Kim W; Choi JE; Jung IK; Kim L; Lee MS
    Hum Psychopharmacol; 2007 Dec; 22(8):501-4. PubMed ID: 17726725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
    Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
    Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An electroencephalographic study of psychiatric inpatients with antipsychotic-induced tardive dyskinesia.
    Koshino Y; Hiramatsu H; Isaki K; Yamaguchi N
    Clin Electroencephalogr; 1986 Jan; 17(1):30-5. PubMed ID: 2869843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia.
    Pourcher E; Cohen H; Cohen D; Baruch P; Bouchard RH
    Brain Cogn; 1993 Sep; 23(1):81-7. PubMed ID: 8105825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
    Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
    Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.
    Spohn HE; Coyne L
    Brain Cogn; 1993 Sep; 23(1):28-39. PubMed ID: 8105820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
    Sweeney JA; Bauer KS; Keshavan MS; Haas GL; Schooler NR; Kroboth PD
    Neuropsychopharmacology; 1997 Mar; 16(3):217-28. PubMed ID: 9138438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tardive dyskinesia in schizophrenics under 60 years of age.
    Kolakowska T; Williams AO; Ardern M; Reveley MA
    Biol Psychiatry; 1986 Feb; 21(2):161-9. PubMed ID: 2868762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tardive dyskinesia and dementia.
    Famuyiwa OO; Eccleston D; Donaldson AA; Garside RF
    Br J Psychiatry; 1979 Dec; 135():500-4. PubMed ID: 43754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anomalous dominance and persistent tardive dyskinesia.
    Barr WB; Mukherjee S; Degreef G; Caracci G
    Biol Psychiatry; 1989 Apr; 25(7):826-34. PubMed ID: 2566333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Eye movement is controlled by basal ganglia-induced GABAergic inhibition].
    Hikosaka O
    Rinsho Shinkeigaku; 1989 Dec; 29(12):1515-8. PubMed ID: 2517048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A potential mechanism underlying the voluntary suppression of tardive dyskinesia.
    Caligiuri MP; Lohr JB
    J Psychiatr Res; 1989; 23(3-4):257-66. PubMed ID: 2576826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
    Thaker GK; Tamminga CA; Alphs LD; Lafferman J; Ferraro TN; Hare TA
    Arch Gen Psychiatry; 1987 Jun; 44(6):522-9. PubMed ID: 3034188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oculomotor signs in a psychiatric population: a preliminary report.
    Karson CN
    Am J Psychiatry; 1979 Aug; 136(8):1057-60. PubMed ID: 37748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.